Int J Angiol 2018; 27(03): 167-173
DOI: 10.1055/s-0038-1661376
Rapid Communication
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Landmark Trials in Cardiology in 2017—Celebrating 40 Years of Angioplasty

Akshyaya Pradhan
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Pravesh Vishwakarma
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Rishi Sethi
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
› Author Affiliations
Further Information

Publication History

Publication Date:
05 July 2018 (online)

Abstract

Cardiovascular (CV) diseases continue to be the leading cause of morbidity and mortality worldwide. Significant progress has been made in the management of coronary artery disease (CAD) and acute coronary syndrome (ACS) over the past 3 decades. The year 2017 marks 40th anniversary of the first coronary angioplasty performed by Andreas Gruentzig in the year 1977. Evidence-based medicine and research has been the key driving force of these positive outcomes. The year 2017 witnessed presentation of several landmark studies at major meetings and many of them getting published in literature simultaneously. These trials evaluated wide range of issues from novel percutaneous coronary intervention (PCI) strategies to newer drugs to innovative devices in management of CAD. We selectively discuss a few major landmark studies that have the potential to alter our daily practice in 2018.

 
  • References

  • 1 Byrne RA, Stone GW, Ormiston J, Kastrati A. Coronary balloon angioplasty, stents, and scaffolds. Lancet 2017; 390 (10096): 781-792
  • 2 Hochman JS, Sleeper LA, Webb JG. , et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999; 341 (09) 625-634
  • 3 Thiele H, Akin I, Sandri M. , et al. Investigators C-S. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017; 377: 2419-2432
  • 4 Elgendy IY, Mahmoud AN, Kumbhani DJ, Bhatt DL, Bavry AA. Complete or culprit-only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: a pairwise and network meta-analysis of randomized trials. JACC Cardiovasc Interv 2017; 10 (04) 315-324
  • 5 Pijls NH, van Schaardenburgh P, Manoharan G. , et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007; 49 (21) 2105-2111
  • 6 Engstrøm T, Kelbæk H, Helqvist S. , et al; DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015; 386 (9994): 665-671
  • 7 Smits PC, Abdel-Wahab M, Neumann FJ. , et al; Compare-Acute Investigators. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med 2017; 376 (13) 1234-1244
  • 8 O'Gara PT, Kushner FG, Ascheim DD. , et al; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61 (04) e78-e140
  • 9 DAPT-Clinical trial results. Available from URL http://www.clincaltrialresults.org/slides/ TCT2017/DAPT-STEMI_kedhi . Accessed March 28, 2018
  • 10 Yeh RW, Secemsky EA, Kereiakes DJ. . DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year a year of percutaneous coronary intervention. JAMA 2016; 315 (16) 1735-1749
  • 11 Suryapranata H. REDUCE: A randomized trial of 3-month vs 12-month DAPT after implantation of a bioabsorbable polymer-based metallic des with a luminal CD34+ antibody coating in patients with ACS. Presented at: Transcatheter cardiovascular therapeutics scientific symposium, October 30–November 2, 2017. Denver, CO
  • 12 Levine GN, Bates ER, Bittl JA. , et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68 (10) 1082-1115
  • 13 Costa F, van Klaveren D, James S. , et al; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389 (10073): 1025-1034
  • 14 Valgimigli M, Bueno H, Byrne RA. , et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
  • 15 Mega JL, Braunwald E, Wiviott SD. , et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
  • 16 Ohman EM, Roe MT, Steg PG. , et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 2017; 389 (10081): 1799-1808
  • 17 Sibbing D, Aradi D, Jacobshagen C. , et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390 (10104): 1747-1757
  • 18 Mohr FW, Morice MC, Kappetein AP. , et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381 (9867): 629-638
  • 19 Farooq V, van Klaveren D, Steyerberg EW. , et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013; 381 (9867): 639-650
  • 20 Escaned J, Collet C, Ryan N. , et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J 2017; 38 (42) 3124-3134
  • 21 Stergiopoulos K, Boden WE, Hartigan P. , et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med 2014; 174 (02) 232-240
  • 22 Al-Lamee R, Thompson D, Dehbi HM. , et al; ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018; 391 (10115): 31-40
  • 23 Eikelboom JW, Connolly SJ, Bosch J. , et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
  • 24 Raal FJ, Stein EA, Dufour R. , et al; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385 (9965): 331-340
  • 25 Sabatine MS, Giugliano RP, Keech AC. , et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722
  • 26 Ridker PM, Everett BM, Thuren T. , et al; CANTOS Trial Group. Anti-inflammatory therapy with canakinumab in atherosclerotic disease. N Engl J Med 2017; 377 (12) 1119-1131
  • 27 Davies JE, Sen S, Dehbi HM. , et al. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med 2017; 376 (19) 1824-1834
  • 28 Götberg M, Christiansen EH, Gudmundsdottir IJ. , et al; iFR-SWEDEHEART Investigators. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med 2017; 376 (19) 1813-1823
  • 29 Reardon MJ, Adams DH, Kleiman NS. , et al. 2-Year outcomes in patients under- going surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol 2015; 66: 121-131
  • 30 Reardon MJ, Van Mieghem NM, Popma JJ. , et al; SURTAVI Investigators. Surgical or transcatheter aortic valve replacement in intermediate risk patients. N Engl J Med 2017; 376 (14) 1321-1331
  • 31 Nishamura RA, Otto CM, Bonow RO. , et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2017; 70 (02) 252-289